top of page

Inflation Reduction Act is destabilizing investment in drug innovation, execs say

The science is there, but not the capital to get certain drugs to market. That means choices are being made, one says.


The Inflation Reduction Act has the consequence of limiting investment in new drugs at a time when the science is there to innovate, pharma executives said during a call with J.P. Morgan analysts this week...



Recent Posts

See All

We Work For Health brings together national and local business leaders, labor, biopharma, patient advocacy, and other healthcare-related stakeholders to support policies and initiatives that foster innovation and facilitate the delivery of lifesaving and life-enhancing medicines. 

We Work For Health. © 2023 All Rights Reserved.

bottom of page